Genworth Financial Inc (GNW) Stock Analysis and Metrics

Genworth Financial

NYSE: GNW

$9.91 ▲ +0.01 (+0.05%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap3.84 Bn

P/E768.44

P/S0.87

Div. Yield0.02

Total Debt (Qtr)1.51 Bn

Revenue Growth (1y) (Qtr)106.15

Add ratio to table…

About

Genworth Financial is a financial services company that primarily provides mortgage insurance through its Enact segment and manages legacy insurance policies through its Closed Block segment while developing aging care services via CareScout.

Revenue is generated from mortgage insurance premiums collected by Enact, fee based income from CareScout Services offering senior care assessments and care plans, and fees from Enact's contract underwriting services, while additional revenue comes from premiums for the new long term care product sold by CareScout Insurance and from capital transfers from Enact to Genworth Holdings to fund strategic initiatives and shareholder returns.

Genworth Financial operates through the following reportable segments: Enact, which consists of private mortgage insurance products, and Closed Block, which consists of long term care, life insurance and annuity products previously sold through legacy insurance subsidiaries.

• Enact: Provides private mortgage insurance covering a portion of the unpaid principal balance of loans with loan to value ratios above 80%, protects lenders against losses, facilitates secondary market sales to government sponsored enterprises, offers primary and pool mortgage insurance, contract underwriting services, uses risk based pricing and loss mitigation techniques.

• Closed Block: Services in force long term care, life insurance and annuity policies that were no longer sold after 2025, implements premium rate increases and benefit reductions to maintain self sustaining operations, and continues to administer claims and policy obligations.

Enact is a leading provider of private mortgage insurance in the United States, competing with five other private insurers and government agencies such as the Federal Housing Administration and the Department of Veterans Affairs, while the Closed Block segment focuses on managing its in force long term care, life insurance and annuity policies through premium rate increases and benefit reductions, positioning the company as a steady operator of legacy policies amid competition from other long term care insurers, and Enact's risk based pricing model enhances its ability to adapt to changing market conditions.

Enact sells its mortgage insurance to lenders and originators across the country including large money center banks, non bank lenders, national and local mortgage bankers, community banks, credit unions, with its largest customer representing 22% of new insurance written and 12% of total revenues in 2025 and the top five lenders together accounting for 33% of new insurance written, while the Closed Block segment serves individual policy holders who hold long term care, life insurance and annuity contracts that remain in force.

Investment Thesis

▲ Bull case

Genworth’s CareScout platform is poised for accelerated monetization in 2026, with management explicitly targeting at least $25 million in services revenue and 7,500 matches—a significant increase from 3,255 in 2025—indicating strong traction in a fragmented long-term care market. The integration of Seniorly expands CareScout’s reach into direct-to-consumer senior living options, credentialing of which is expected to be complete by end-2026, unlocking new B2B and consumer channels. This vertical integration of services, assessments, care planning, and insurance (Care Assurance) creates a sticky, recurring-revenue ecosystem that leverages Genworth’s 40+ years of claims data and AI-driven underwriting to reduce acquisition costs and improve risk selection. Crucially, CareScout services are designed to feed future insurance demand by engaging adult children of baby boomers who witness their parents’ care struggles—a demographic representing ~70 million potential future policyholders. With Care Assurance now live in 40 states and pricing reflecting a conservative, durable structure aligned with today’s LTC environment, the product avoids the pitfalls of legacy LTC offerings while differentiating through bundled services like CQN access and wellness tools. This holistic approach addresses unmet demand for transparent, coordinated care solutions in a market where Medicaid sustainability is under bipartisan scrutiny, positioning CareScout as a capital-light, scalable platform that could drive durable growth independent of the runoff Closed Block.
Enact’s sustained capital generation remains an underappreciated anchor for Genworth’s financial flexibility, with $407 million returned to Genworth in 2025 and an expected $405 million in 2026 based on Enact’s $500 million share repurchase authorization and Genworth’s ~81% ownership. Despite market concerns about mortgage rate volatility, Enact’s PMIERs sufficiency ratio remained strong at 162% (~$1.9 billion above requirements) and its loss ratio of 7% reflects exceptional underwriting discipline, supported by a net reserve release of $60 million in Q4 FY25 driven by continued strong cure performance. This consistent cash flow enables Genworth to fund CareScout investments ($50–$55 million planned for services in 2026) and maintain its share repurchase program ($175–$225 million target for 2026) without relying on external financing or jeopardizing balance sheet strength. Notably, Genworth has reduced shares outstanding by ~24% since May 2022 through repurchases totaling ~$828 million, creating long-term value by deploying capital at prices management believes represent a discount to intrinsic value. Enact’s book value attributable to Genworth grew to $4.4 billion at year-end 2025 from $4.1 billion in 2024, underscoring its role as a compounding asset that supports both growth initiatives and shareholder returns. The market may be underestimating how this steady capital return stream de-risks Genworth’s transition to a growth-oriented model, allowing patient investment in CareScout while maintaining financial flexibility for opportunistic debt reduction or bolt-on acquisitions in the services space.
Genworth’s Closed Block risk mitigation is progressing more effectively than headline GAAP losses suggest, with management highlighting that benefit reductions and premium rate increases have achieved ~$34.5 billion in net present value since 2012—including $1 billion in 2025 approvals—and reduced exposure to the riskiest LTC features, such as the 5% compound benefit inflation option (down to <36% from 57% in 2014) and lifetime benefits (now 11% of policies). Notably, ~61% of policyholders offered benefit reductions have elected them, directly lowering long-term tail risk. The value from these reductions is further amplified by assumption updates, which added $2.3 billion in recognized value in 2025 alone, with ~$5 billion remaining to be captured. Concurrently, innovative risk-mitigation tools like the CareScout Quality Network (providing direct claim savings via provider discounts) and the Live Well | Age Well program (delaying claim onset through preventive engagement) are matured enough to deliver measurable savings—management expects $1 billion to $1.5 billion in NPV claim savings over time—and are being integrated into future assumption reviews. While GAAP results reflect remeasurement volatility from short-term experience vs. long-term assumptions (averaging ~$75 million/quarter in LTC A/E losses), the statutory pretax income of $71 million for FY25 and GLIC’s 300% RBC ratio demonstrate underlying economic resilience. Crucially, Genworth explicitly stated it will not inject capital into the Closed Block, relying instead on in-force management to achieve self-sustainability—a credible strategy given the long-tail nature of liabilities and peak claim years still over a decade away. This disciplined approach, combined with ongoing rate action progress, suggests the Closed Block may become less of a drag and more of a stable, runoff asset than the market anticipates.

Genworth’s CareScout platform is poised for accelerated monetization in 2026, with management explicitly targeting at least $25 million in services revenue and 7,500 matches—a significant increase from 3,255 in 2025—indicating strong traction in a fragmented long-term care market. The integration of Seniorly expands CareScout’s reach into direct-to-consumer senior living options, credentialing of which is expected to be complete by end-2026, unlocking new B2B and consumer channels. This vertical integration of services, assessments, care planning, and insurance (Care Assurance) creates a sticky, recurring-revenue ecosystem that leverages Genworth’s 40+ years of claims data and AI-driven underwriting to reduce acquisition costs and improve risk selection. Crucially, CareScout services are designed to feed future insurance demand by engaging adult children of baby boomers who witness their parents’ care struggles—a demographic representing ~70 million potential future policyholders. With Care Assurance now live in 40 states and pricing reflecting a conservative, durable structure aligned with today’s LTC environment, the product avoids the pitfalls of legacy LTC offerings while differentiating through bundled services like CQN access and wellness tools. This holistic approach addresses unmet demand for transparent, coordinated care solutions in a market where Medicaid sustainability is under bipartisan scrutiny, positioning CareScout as a capital-light, scalable platform that could drive durable growth independent of the runoff Closed Block.
Enact’s sustained capital generation remains an underappreciated anchor for Genworth’s financial flexibility, with $407 million returned to Genworth in 2025 and an expected $405 million in 2026 based on Enact’s $500 million share repurchase authorization and Genworth’s ~81% ownership. Despite market concerns about mortgage rate volatility, Enact’s PMIERs sufficiency ratio remained strong at 162% (~$1.9 billion above requirements) and its loss ratio of 7% reflects exceptional underwriting discipline, supported by a net reserve release of $60 million in Q4 FY25 driven by continued strong cure performance. This consistent cash flow enables Genworth to fund CareScout investments ($50–$55 million planned for services in 2026) and maintain its share repurchase program ($175–$225 million target for 2026) without relying on external financing or jeopardizing balance sheet strength. Notably, Genworth has reduced shares outstanding by ~24% since May 2022 through repurchases totaling ~$828 million, creating long-term value by deploying capital at prices management believes represent a discount to intrinsic value. Enact’s book value attributable to Genworth grew to $4.4 billion at year-end 2025 from $4.1 billion in 2024, underscoring its role as a compounding asset that supports both growth initiatives and shareholder returns. The market may be underestimating how this steady capital return stream de-risks Genworth’s transition to a growth-oriented model, allowing patient investment in CareScout while maintaining financial flexibility for opportunistic debt reduction or bolt-on acquisitions in the services space.
Genworth’s Closed Block risk mitigation is progressing more effectively than headline GAAP losses suggest, with management highlighting that benefit reductions and premium rate increases have achieved ~$34.5 billion in net present value since 2012—including $1 billion in 2025 approvals—and reduced exposure to the riskiest LTC features, such as the 5% compound benefit inflation option (down to <36% from 57% in 2014) and lifetime benefits (now 11% of policies). Notably, ~61% of policyholders offered benefit reductions have elected them, directly lowering long-term tail risk. The value from these reductions is further amplified by assumption updates, which added $2.3 billion in recognized value in 2025 alone, with ~$5 billion remaining to be captured. Concurrently, innovative risk-mitigation tools like the CareScout Quality Network (providing direct claim savings via provider discounts) and the Live Well | Age Well program (delaying claim onset through preventive engagement) are matured enough to deliver measurable savings—management expects $1 billion to $1.5 billion in NPV claim savings over time—and are being integrated into future assumption reviews. While GAAP results reflect remeasurement volatility from short-term experience vs. long-term assumptions (averaging ~$75 million/quarter in LTC A/E losses), the statutory pretax income of $71 million for FY25 and GLIC’s 300% RBC ratio demonstrate underlying economic resilience. Crucially, Genworth explicitly stated it will not inject capital into the Closed Block, relying instead on in-force management to achieve self-sustainability—a credible strategy given the long-tail nature of liabilities and peak claim years still over a decade away. This disciplined approach, combined with ongoing rate action progress, suggests the Closed Block may become less of a drag and more of a stable, runoff asset than the market anticipates.

▼ Bear case

CareScout’s path to profitability remains uncertain and capital-intensive, with management acknowledging it will “take time to scale these businesses and reach breakeven” despite targeting only $25 million in services revenue for 2026—a figure that implies significant operating leverage is required to cover planned $50–$55 million in annual investments. The platform’s reliance on evolving B2B partnerships (e.g., employee assistance programs, carriers) and direct-to-consumer adoption introduces execution risk, particularly as Seniorly’s integration—while progressing well—has not yet demonstrated measurable contribution to match volumes or revenue beyond credentialing efforts slated for completion by end-2026. Care Assurance, though launched in 40 states, faces slow adoption as management concedes it will “build gradually,” and its success hinges on converting CareScout services users into insurance buyers—a behavioral shift unproven at scale. Moreover, the LTC insurance market remains structurally challenged by low consumer demand, with CareScout services targeting the 95% of baby boomers who never bought LTC insurance, suggesting a high education and trust-building burden. Without clear evidence of margin expansion or reduced customer acquisition costs, the $50–$55 million annual investment in CareScout services could become a persistent drag on holding company liquidity, especially if Enact’s capital returns face headwinds from mortgage market cycles or regulatory changes affecting private mortgage insurance profitability.
Enact’s capital generation, while strong today, is vulnerable to cyclical and structural risks in the mortgage insurance sector that Genworth may be underestimating. Although Enact’s PMIERs ratio of 162% and $1.9 billion surplus appear robust, these metrics are sensitive to changes in mortgage delinquency rates and housing market stress—factors not discussed in depth during the call despite ongoing macroeconomic uncertainty. Enact’s book value growth to $4.4 billion reflects prior success but does not guarantee future returns, especially if rising interest rates suppress refinancing activity (a historical driver of new insurance written) or if increased competition from GSEs or private capital compresses margins. Genworth’s dependence on Enact for ~$405 million in annual cash flow creates concentration risk; any sustained decline in Enact’s profitability would directly impair Genworth’s ability to fund CareScout investments and maintain share repurchases without increasing leverage. Furthermore, Enact’s new $500 million share repurchase authorization, while positive, requires Genworth to participate to maintain its ~81% ownership, potentially limiting flexibility to deploy capital elsewhere if Enact’s stock becomes overvalued relative to intrinsic value—a nuance not addressed when management cited repurchases as deploying capital at “discounts to intrinsic value.”
The Closed Block’s long-term sustainability is increasingly doubtful given persistent GAAP losses and conservative statutory metrics that may mask deteriorating fundamentals. Despite highlighting ~$34.5 billion in NPV from rate actions since 2012, management acknowledged that LTC A/E losses averaged ~$75 million per quarter in 2025 due to unfavorable actual vs. expected experience in capped cohorts, with the potential to continue at this level in 2026. While benefit reductions have lowered exposure to high-risk features (e.g., 5% compound inflation to <36%), the remaining ~$5 billion in value to be achieved assumes successful future rate approvals and benefit reductions—both of which face headwinds from state regulatory pushback on premium increases and policyholder resistance. The Live Well | Age Well and CareScout Quality Network initiatives, though promising, remain unproven at scale for delivering the $1–$1.5 billion in NPV claim savings cited, with no specifics on current savings realization or adoption rates. Statutory pretax income of $71 million for FY25 was down sharply from the prior year’s $355 million benefit from LTC legal settlements (now materially complete), revealing how much of the block’s recent profitability relied on non-recurring items. GLIC’s RBC ratio decline to 300% (from 306%) reflects growing required capital from limited partnership investments, suggesting the buffer against adverse LTC experience may be eroding even as statutory earnings exclude the impact of GAAP remeasurement volatility. Without new sales and with claim payments still over a decade from peaking, the Closed Block’s long-term viability hinges on optimistic assumptions about future mortality, lapse rates, and inflation control—assumptions that could unravel if macroeconomic or healthcare trends worsen faster than anticipated.

CareScout’s path to profitability remains uncertain and capital-intensive, with management acknowledging it will “take time to scale these businesses and reach breakeven” despite targeting only $25 million in services revenue for 2026—a figure that implies significant operating leverage is required to cover planned $50–$55 million in annual investments. The platform’s reliance on evolving B2B partnerships (e.g., employee assistance programs, carriers) and direct-to-consumer adoption introduces execution risk, particularly as Seniorly’s integration—while progressing well—has not yet demonstrated measurable contribution to match volumes or revenue beyond credentialing efforts slated for completion by end-2026. Care Assurance, though launched in 40 states, faces slow adoption as management concedes it will “build gradually,” and its success hinges on converting CareScout services users into insurance buyers—a behavioral shift unproven at scale. Moreover, the LTC insurance market remains structurally challenged by low consumer demand, with CareScout services targeting the 95% of baby boomers who never bought LTC insurance, suggesting a high education and trust-building burden. Without clear evidence of margin expansion or reduced customer acquisition costs, the $50–$55 million annual investment in CareScout services could become a persistent drag on holding company liquidity, especially if Enact’s capital returns face headwinds from mortgage market cycles or regulatory changes affecting private mortgage insurance profitability.
Enact’s capital generation, while strong today, is vulnerable to cyclical and structural risks in the mortgage insurance sector that Genworth may be underestimating. Although Enact’s PMIERs ratio of 162% and $1.9 billion surplus appear robust, these metrics are sensitive to changes in mortgage delinquency rates and housing market stress—factors not discussed in depth during the call despite ongoing macroeconomic uncertainty. Enact’s book value growth to $4.4 billion reflects prior success but does not guarantee future returns, especially if rising interest rates suppress refinancing activity (a historical driver of new insurance written) or if increased competition from GSEs or private capital compresses margins. Genworth’s dependence on Enact for ~$405 million in annual cash flow creates concentration risk; any sustained decline in Enact’s profitability would directly impair Genworth’s ability to fund CareScout investments and maintain share repurchases without increasing leverage. Furthermore, Enact’s new $500 million share repurchase authorization, while positive, requires Genworth to participate to maintain its ~81% ownership, potentially limiting flexibility to deploy capital elsewhere if Enact’s stock becomes overvalued relative to intrinsic value—a nuance not addressed when management cited repurchases as deploying capital at “discounts to intrinsic value.”
The Closed Block’s long-term sustainability is increasingly doubtful given persistent GAAP losses and conservative statutory metrics that may mask deteriorating fundamentals. Despite highlighting ~$34.5 billion in NPV from rate actions since 2012, management acknowledged that LTC A/E losses averaged ~$75 million per quarter in 2025 due to unfavorable actual vs. expected experience in capped cohorts, with the potential to continue at this level in 2026. While benefit reductions have lowered exposure to high-risk features (e.g., 5% compound inflation to <36%), the remaining ~$5 billion in value to be achieved assumes successful future rate approvals and benefit reductions—both of which face headwinds from state regulatory pushback on premium increases and policyholder resistance. The Live Well | Age Well and CareScout Quality Network initiatives, though promising, remain unproven at scale for delivering the $1–$1.5 billion in NPV claim savings cited, with no specifics on current savings realization or adoption rates. Statutory pretax income of $71 million for FY25 was down sharply from the prior year’s $355 million benefit from LTC legal settlements (now materially complete), revealing how much of the block’s recent profitability relied on non-recurring items. GLIC’s RBC ratio decline to 300% (from 306%) reflects growing required capital from limited partnership investments, suggesting the buffer against adverse LTC experience may be eroding even as statutory earnings exclude the impact of GAAP remeasurement volatility. Without new sales and with claim payments still over a decade from peaking, the Closed Block’s long-term viability hinges on optimistic assumptions about future mortality, lapse rates, and inflation control—assumptions that could unravel if macroeconomic or healthcare trends worsen faster than anticipated.

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Companies in the Insurance - Life

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	PUK	Prudential Plc	75.05 Bn	13.61	6.53	4.46 Bn
2	AFL	Aflac Inc	63.80 Bn	13.76	3.85	-
3	MET	Metlife Inc	60.34 Bn	17.57	0.85	0.70 Bn
4	MFC	Manulife Financial Corp	52.65 Bn	16.01	-	4.69 Bn
5	UNM	Unum Group	14.19 Bn	18.64	1.24	3.76 Bn
6	PRI	Primerica, Inc.	9.76 Bn	51.35	5.47	0.60 Bn
7	JXN	Jackson Financial Inc.	8.17 Bn	-19.44	0.75	2.08 Bn
8	LNC	Lincoln National Corp	7.81 Bn	4.79	0.41	6.37 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password